Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At vTv Therapeutics (NASDAQ:VTVT), a filing with the SEC revealed that on Friday, Ronald O. Perelman bought 570,776 shares of VTVT, at a cost of $4.38 each, for a total investment of $2.5M. Investors have the opportunity to buy VTVT at a price even lower than Perelman did, with shares changing hands as low as $1.46 at last check today which is 66.7% under Perelman's purchase price. vTv Therapeutics is trading up about 2.8% on the day Wednesday. Before this latest buy, Perelman purchased VTVT at 5 other times during the past twelve months, for a total cost of $929,551 at an average of $4.32 per share.
And at Dermira (NASDAQ:DERM), there was insider buying on Monday, by CEO & Chairman of the Board Thomas G. Wiggans who purchased 12,000 shares at a cost of $10.00 each, for a total investment of $119,951. Before this latest buy, Wiggans purchased DERM at 2 other times during the past year, for a total investment of $239,584 at an average of $9.24 per share. Dermira Inc is trading off about 1.4% on the day Wednesday. Wiggans was up about 9.4% on the buy at the high point of today's trading session, with DERM trading as high as $10.94 in trading on Wednesday.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.